StreetInsider.com News Articles

RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)

Tue, 01 Sep 2026 08:56:13 -0400

RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $737.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst commented: "A Restructured SNY Collab Would Be Strategic, Though Likely Take Time To Drive Value; Given our sense of growing anticipation for renegotiated REGNSNY deal terms to accommodate next-gen assets, perhaps as soon as late-'26/early-'27, we examined different scenarios in depth. Both parties should be incentivized to get a deal done, and we believe the most likely outcome is REGN obtains more equitable/favorable terms (likely 50/50 global profit share or better) for next-gen I&I assets they contribute, SNY perhaps

Form 4 REGENERON PHARMACEUTICAL For: Aug 19 Filed by: LAROSA JOSEPH J

Fri, 21 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26961290.html

Form 4 REGENERON PHARMACEUTICAL For: Aug 19 Filed by: LAROSA JOSEPH J

Fri, 21 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26961290.html

Form N-PX REGENERON PHARMACEUTICAL For: Jun 30

Thu, 20 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26956298.html

Form N-PX REGENERON PHARMACEUTICAL For: Jun 30

Thu, 20 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26956298.html

Form 4 REGENERON PHARMACEUTICAL For: Aug 18 Filed by: Fenimore Christopher R.

Thu, 20 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260820/26956085.html

Form 4 REGENERON PHARMACEUTICAL For: Aug 18 Filed by: Fenimore Christopher R.

Thu, 20 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260820/26956085.html

Regeneron Announces Investor Conference Presentations

Wed, 19 Aug 2026 16:05:00 -0400

TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026
Morgan Stanley 24^th Annual Global Healthcare Conference at 1:05 p.m. ET on Monday, September 14, 2026
Bernstein Insights: Healthcare Leaders and Disruptors – 3^rd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, September 23, 2026

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will

Regeneron Announces Investor Conference Presentations

Wed, 19 Aug 2026 16:05:00 -0400

TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026
Morgan Stanley 24^th Annual Global Healthcare Conference at 1:05 p.m. ET on Monday, September 14, 2026
Bernstein Insights: Healthcare Leaders and Disruptors – 3^rd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, September 23, 2026

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will

FDA approves Regeneron's Pasatru for rare bone disorder FOP

Wed, 19 Aug 2026 13:58:35 -0400

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the U.S. Food and Drug Administration has approved Pasatru (garetosmab-grts) to reduce the formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP), according to a company press release.

FOP is an ultra-rare genetic disorder in which muscles, tendons, ligaments and other connective tissues are progressively infiltrated by abnormal bone formation. Approximately 900 people worldwide are diagnosed with FOP. Most patients are wheelchair-bound by age 30, and the median age of survival is 56.

The approval is based on results from the Phase 3 OPTIMA trial, which enrolled 63

FDA approves Regeneron's Pasatru for rare bone disorder FOP

Wed, 19 Aug 2026 13:58:35 -0400

The approval is based on results from the Phase 3 OPTIMA trial, which enrolled 63

FDA approves Regeneron's Pasatru for rare bone disorder FOP

Wed, 19 Aug 2026 13:58:35 -0400

The approval is based on results from the Phase 3 OPTIMA trial, which enrolled 63

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i

Wed, 19 Aug 2026 13:58:00 -0400

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability